Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity

Stefano Arcangeli, Barbara Alicia Jereczek-Fossa, Filippo Alongi, Cynthia Aristei, Carlotta Becherini, Liliana Belgioia, Michela Buglione, Luciana Caravatta, Rolando Maria D'Angelillo, Andrea Riccardo Filippi, Michele Fiore, Domenico Genovesi, Carlo Greco, Lorenzo Livi, Stefano Maria Magrini, Giulia Marvaso, Rosario Mazzola, Icro Meattini, Anna Merlotti, Isabella PalumboStefano Pergolizzi, Sara Ramella, Umberto Ricardi, Elvio Russi, Marco Trovò, Alessandro Sindoni, Vincenzo Valentini, Renzo Corvò

Research output: Contribution to journalArticlepeer-review

Abstract

Clinical development and use of novel systemic agents in combination with radiotherapy (RT) is at nowadays most advanced in the field of treatment of solid tumors. Although for many of these substances preclinical studies provide sufficient evidences on their principal capability to enhance radiation effects, the majority of them have not been investigated in even phase I clinical trials for safety in the context of RT. In clinical practice, unexpected acute and late side effects may emerge especially in combination with RT. As a matter of fact, despite combined modality treatment holds potential for enhancing the therapeutic ratio, some concerns are raised from the lack of high-quality clinical data to guide the care of patients who are treated with novel compounds in conjunction with RT. The aim of this review is to provide, from a radio-oncological point of view, an overview of the most advanced combined treatment concepts for solid tumors focusing on treatment toxicity.

Original languageEnglish
JournalCritical Reviews in Oncology/Hematology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Keywords

  • Radiotherapy
  • Systemic compounds
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity'. Together they form a unique fingerprint.

Cite this